Prevalence of post-acute coronavirus disease 2019 symptoms twelve months after hospitalization in participants retained in follow-up: analyses strati fi ed by gender from a large prospective cohort

Objectives: Persistent post-acute coronavirus disease 2019 (COVID-19) symptoms (PACSs) have been reported up to 6 months after hospital discharge. Herein we assessed the symptoms that

[1]  J. Cervilla,et al.  Long COVID 12 months after discharge: persistent symptoms in patients hospitalised due to COVID-19 and patients hospitalised due to other causes—a multicentre cohort study , 2022, BMC Medicine.

[2]  K. Kwon,et al.  Post-acute COVID-19 syndrome in patients after 12 months from COVID-19 infection in Korea , 2022, BMC Infectious Diseases.

[3]  A. Slooter,et al.  Clinical Outcomes Among Patients With 1-Year Survival Following Intensive Care Unit Treatment for COVID-19. , 2022, JAMA.

[4]  Janet Diaz,et al.  A clinical case definition of post-COVID-19 condition by a Delphi consensus , 2021, The Lancet Infectious Diseases.

[5]  G. Martin-Blondel,et al.  Severity of self-reported symptoms and psychological burden 6-months after hospital admission for COVID-19: a prospective cohort study , 2021, International Journal of Infectious Diseases.

[6]  F. Limosin,et al.  Association Between Psychological Distress, Cognitive Complaints, and Neuropsychological Status After a Severe COVID-19 Episode: A Cross-Sectional Study , 2021, Frontiers in Psychiatry.

[7]  J. Geddes,et al.  Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19 , 2021, PLoS medicine.

[8]  A. Nath,et al.  Acute and chronic neurological disorders in COVID-19: potential mechanisms of disease , 2021, Brain : a journal of neurology.

[9]  Ting Yu,et al.  1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study , 2021, The Lancet.

[10]  K. Sparrer,et al.  Implications of Innate Immunity in Post-Acute Sequelae of Non-Persistent Viral Infections , 2021, Cells.

[11]  G. Wegener,et al.  Psychiatric and neuropsychiatric sequelae of COVID-19 – A systematic review , 2021, Brain, Behavior, and Immunity.

[12]  I. Guessous,et al.  Prevalence of Symptoms More Than Seven Months After Diagnosis of Symptomatic COVID-19 in an Outpatient Setting , 2021, Annals of Internal Medicine.

[13]  U. Merle,et al.  Persistent Symptoms in Adult Patients 1 Year After Coronavirus Disease 2019 (COVID-19): A Prospective Cohort Study , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  I. Tleyjeh,et al.  Unraveling the Mystery Surrounding Post-Acute Sequelae of COVID-19 , 2021, Frontiers in Immunology.

[15]  C. Chan,et al.  Residual SARS-CoV-2 viral antigens detected in GI and hepatic tissues from five recovered patients with COVID-19 , 2021, Gut.

[16]  C. Schmidt,et al.  Bidimensional structure and measurement equivalence of the Patient Health Questionnaire-9: sex-sensitive assessment of depressive symptoms in three representative German cohort studies , 2021, BMC Psychiatry.

[17]  F. Mentré,et al.  Persistent COVID-19 symptoms are highly prevalent 6 months after hospitalization: results from a large prospective cohort , 2021, Clinical Microbiology and Infection.

[18]  M. Beutel,et al.  Similarities and Differences of Mental Health in Women and Men: A Systematic Review of Findings in Three Large German Cohorts , 2021, Frontiers in Public Health.

[19]  T. Jafar,et al.  Factors associated with psychological distress during the coronavirus disease 2019 (COVID-19) pandemic on the predominantly general population: A systematic review and meta-analysis , 2020, PloS one.

[20]  P. Weihe,et al.  Long COVID in the Faroe Islands - a longitudinal study among non-hospitalized patients , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  M. Nussenzweig,et al.  Evolution of Antibody Immunity to SARS-CoV-2 , 2020, bioRxiv.

[22]  Y. Yazdanpanah.  Impact on disease mortality of clinical, biological, and virological characteristics at hospital admission and overtime in COVID‐19 patients , 2020, Journal of medical virology.

[23]  F. Bruyère,et al.  Follow-up of adults with noncritical COVID-19 two months after symptom onset , 2020, Clinical Microbiology and Infection.

[24]  Jordan J. Clark,et al.  Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score , 2020, BMJ.

[25]  P. Horby,et al.  Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study , 2020, BMJ.

[26]  E. Botelho-nevers,et al.  P-07: L’optimisation T2A du codage PMSI pénalise-t-elle le reflet de l’activité médicale d’un service des maladies infectieuses et tropicales ? , 2014 .

[27]  Peter Henningsen,et al.  Management of functional somatic syndromes , 2007, The Lancet.